About three in four women going through the menopause transition experience hot flashes, and the median duration of frequent symptoms is roughly 7.4 years according to the landmark SWAN study. They are not just an inconvenience. Severe hot flashes are linked to sleep loss, lower productivity, and worse cardiovascular and bone outcomes. The good news is that 2024-era treatment options are far better than they were even a decade ago, with both hormonal and effective non-hormonal medications now available.
What Hot Flashes Are and How Common They Are
A hot flash is a sudden sensation of intense heat — usually starting in the chest, neck, or face — accompanied by flushing, sweating, and sometimes a chilled aftermath. Episodes typically last one to five minutes. When they occur during sleep and produce drenching sweat, they are called night sweats. Together they are termed vasomotor symptoms.
According to the North American Menopause Society, approximately 75 to 80 percent of women experience hot flashes during the menopause transition. The SWAN study found Black women experience them more frequently and for longer durations than other groups, and women of higher BMI tend to have more severe symptoms. About 10 to 20 percent of women find hot flashes severely debilitating. For wider context on the menopausal transition, see our medical conditions hub.
What Causes Hot Flashes
Hot flashes arise from a narrowed thermoregulatory zone in the hypothalamus. Estrogen withdrawal alters signaling in the kisspeptin/neurokinin B/dynorphin (KNDy) neurons of the hypothalamus, which are responsible for body temperature regulation. The 2018 review in Endocrinology describes how this disrupted signaling triggers inappropriate heat-dissipation responses — vasodilation and sweating — even when core body temperature has not actually risen.
This neurobiological understanding is why fezolinetant, a neurokinin 3 receptor antagonist that acts directly on KNDy neurons, became the first non-hormonal pathway-targeted treatment for hot flashes when the FDA approved Veozah in May 2023.
Triggers That Can Make Hot Flashes Worse
While the underlying cause is neuroendocrine, day-to-day triggers can precipitate individual episodes. Common ones include warm rooms, hot drinks, spicy foods, alcohol (especially red wine), caffeine, smoking, stress, and tight or synthetic clothing. Mayo Clinic notes that identifying personal triggers is one of the simplest first steps, though for many women, lifestyle modification alone is not enough.
Hot flashes can also occur outside of perimenopause and menopause. Tamoxifen, aromatase inhibitors, GnRH agonists, surgical menopause, opioid withdrawal, and some SSRIs can cause vasomotor symptoms. Less commonly, thyroid dysfunction, carcinoid syndrome, or pheochromocytoma cause flushing episodes that may be mistaken for hot flashes.
How Hot Flashes Are Evaluated
For women in the menopause transition, no testing is needed to diagnose hot flashes — the clinical history is sufficient. Evaluation focuses on whether something else might be contributing and what treatment is appropriate. A clinician will typically review medications, ask about sleep, mood, cardiovascular history, breast cancer history, and clotting risk factors.
Lab testing may include TSH if thyroid disease is suspected, since hyperthyroidism can mimic flushing and heat intolerance. According to ACOG, FSH testing is not routinely useful for diagnosis in symptomatic women over 45. When hot flashes occur in younger women, broader workup for primary ovarian insufficiency, medications, and rare causes may be appropriate.
Treatment Options
Hormone therapy remains the most effective treatment, reducing hot flash frequency and severity by approximately 75 percent in clinical trials. The 2022 NAMS Hormone Therapy Position Statement supports systemic menopausal hormone therapy as first-line for moderate to severe vasomotor symptoms in healthy women under 60 or within 10 years of menopause, when contraindications are absent.
For women who cannot or prefer not to use hormones, several non-hormonal prescriptions have evidence. Low-dose paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal product for hot flashes, but other SSRIs and SNRIs — venlafaxine, escitalopram, citalopram, and desvenlafaxine — also reduce hot flashes by roughly 25 to 65 percent in trials. Gabapentin (especially for night-time symptoms) and oxybutynin are additional options. Fezolinetant 45 mg daily reduced moderate-to-severe hot flashes by about 60 percent versus 45 percent for placebo in the SKYLIGHT trials published in The Lancet.
Non-pharmacologic approaches with reasonable evidence include cognitive behavioral therapy, clinical hypnosis, and weight loss for women with overweight or obesity. The NAMS 2023 Nonhormone Therapy Position Statement specifically notes good evidence for CBT and hypnosis. Common practices like soy isoflavones, black cohosh, and yoga have mixed or modest evidence.
When to See a Doctor
Many women manage mild hot flashes with simple lifestyle adjustments and never need a clinician’s help. But when symptoms disrupt sleep most nights, affect work performance, or persist for years without improvement, a conversation about prescription options is reasonable. Women under age 45 with new vasomotor symptoms should be evaluated for early menopause, medication effects, or other causes.
Hot flashes accompanied by other concerning features deserve prompt assessment. Episodes with diarrhea, wheezing, or facial flushing that follows specific foods may suggest carcinoid. Drenching night sweats with weight loss or fevers can signal infection or malignancy.
When to seek emergency care: Call 911 or go to the nearest emergency room if a hot flash episode is accompanied by chest pain, severe shortness of breath, fainting, sudden severe headache, one-sided weakness or speech changes, or any features suggesting a heart attack, stroke, or anaphylaxis.
Frequently Asked Questions
How long do hot flashes last?
The SWAN study found a median duration of frequent vasomotor symptoms of 7.4 years from onset, with about a third of women having symptoms for more than 10 years. Women whose hot flashes start in early perimenopause tend to have the longest courses.
Can men get hot flashes?
Yes. Men on androgen deprivation therapy for prostate cancer commonly develop hot flashes, and the same neurobiological mechanism applies. Treatment options overlap with those used for women, including SSRIs and gabapentin.
Do natural remedies actually work?
Evidence is mixed. Black cohosh, soy isoflavones, and red clover have shown modest benefit in some trials and no benefit in others. NAMS does not recommend them as first-line therapy. Cognitive behavioral therapy and clinical hypnosis have stronger evidence than most herbal options.
Is fezolinetant safer than hormone therapy?
Fezolinetant avoids the breast and clotting risks associated with hormones but requires monitoring of liver enzymes due to rare elevations seen in trials. NAMS considers it a reasonable option for women who cannot or do not wish to use hormone therapy. Cost and insurance coverage are practical considerations.
The Bottom Line
Hot flashes are common, often long-lasting, and treatable. Hormone therapy works best for women without contraindications, but several effective non-hormonal options exist for those who cannot or prefer not to use hormones. If symptoms are disrupting sleep, work, or daily life, a clinician familiar with current menopause guidelines can help match treatment to your individual risk profile and preferences. Tracking trigger patterns, episodes per day, and night-time symptoms before your visit makes the conversation more productive.